1244921 A7 B7 五、發明説明（1 ) 本發明係有關口服藥劑，更詳細者係有關提高雙苯醯 硫胺吸收性之口服藥劑。 (請先閱讀背面之注意事項再填寫本頁) 先行技術中，維生素係以糖質、脂質、蛋白質做爲能 源生體構成成份被利用時爲必要成份者。現今，已不常出 現等古典型維生素缺乏症者，惟，當維生素不足時，則出 現疲勞、倦怠、食慾不振等症狀。甚至，抽煙，壓力會增 加維生素C之消耗量、喝酒會增加維生素B i之消耗量，造 成維生素C、B i之不足，潛在性維生素缺乏症或境界型維 生素缺乏在現今亦並非不存在者。 維生素中，維生素B i、維生素C等水溶性維生素即使 大量攝取亦馬上於尿中排泄，因此，只須攝取每日必要量 即可。惟，依每天三餐攝取必要水溶性維他命並不是很容 易。因此，常以其不足水溶性維他命之維生素劑進行補給 者。 經濟部智慧財產局員工消費合作社印製 而，通常水溶性維生素之吸收比脂溶性維生素較佳， 惟，水溶性維生素亦出現諸多消化管吸收問題。如：水溶 性維他命之一的維生素B i於消化管之吸收有限，易排泄於 體外，且，當腸內釋出硫胺素酶之菌時，則呈維生素B 1缺 乏症者爲公知者。 因此，爲改善維生素B :缺乏症、改善治療所使用之鹽 酸硫胺等於消化管中之吸收、被討論增加維生素B 1之脂溶 性衍生物者，做爲此易吸收性衍生物者進行合成辛硫胺、 苯磷硫胺、乙氧羰硫胺、賽可硫胺、二硫硫胺、雙苯醯硫 胺、雙異硫胺等係藉此取得更高血中濃度。惟，於該雙苯 -4 - 本紙張尺度適用中國國家標準（CNS ) A4規格（210X 297公釐） 1244921 A7 B7 五、發明説明（2 ) 醯硫胺中，藉由添加賦形劑等添加物後其吸收性差爲公知 者故被期待提供一種由消化管之吸收爲最適化之處方。 (請先閱讀背面之注意事項再填寫本頁) 因此，本發明係以提供一種吸收性更理想之維他命B 1 含有製劑做爲其課題者。 鑑於此情況，本發明者進行各種維生素B :之消化管吸 收性的精密硏討後結果意外發現，於雙苯醯硫胺摻合發煙 脂與維生素E時，可迅速由消化管吸收雙苯醯硫胺之吸收 ，且，增加血漿中硫胺量者，進而完成本發明。 亦即，本發明之特徵係提供一種摻合雙苯醯硫胺、發 煙脂及維生素E之口服藥劑者。 〔發明實施之形態〕 本發明口服藥劑（以下稱「本發明製劑」）中所使用 之雙苯醯硫胺爲化學名：Ν’-Ι^ΐΜοΙ^Ι^-Ι^-ί^βηζογΙοχ^-θΐΙιγΙ]- l-methyl-2, l-ethenediyl]]bis[N-[(4_amino-2-methyl-5-pyrimidinyl)methyl]formamide]、分子式： 經濟部智慧財產局員工消費合作社印製 C 3 8 Η 4 2 N 8 0 6 S 2 ,分子量：7 7 0 . 9 3之硫胺衍生 物者、1 1 4 m g之雙苯醯硫胺相當於1 〇 〇 m g鹽酸硫 胺之化合物者。 又，本發明製劑中所使用之發煙脂（化學名：2-1^\71-(2-hydroxymethyl)-l，3-propandiol trinicotinate )爲具有改 善血流作用、抑制血小板凝聚作用、纖維素溶解作用等藥 理效果之末梢血管擴張劑者，做爲雷諾氏病、脫疸特發性 疾病、阻塞性動脈硬化症等末梢循環障礙、凍瘡、凍傷藥 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -5- 1244921 A7 _ B7 五、發明説明（3 ) 被使用之化合物者。 (請先閱讀背面之注意事項再填寫本頁) 更且，本發明製劑中所使用之維生素E係指一般維他 命總稱所有化合物者、理想之具體例如：琥珀酸d 一 α 一 生育酚、琥珀酸d 1 - α -生育酚、琥珀酸d 1 - α 一生 育酚鈣、醋酸d - α -生育酚、醋酸d 1 - α -生育酚、 d — α —生育酚、dl—α —生育酚等例。 本發明製劑中其雙苯醯硫胺、發煙脂、及維生素E之 摻合量針對1重量份雙苯醯硫胺時，發煙脂爲〇 . 3〜 3 0 0重量份者、維生素E爲0 . 3〜3 0 0重量份者， 較佳者當1重量份雙苯醯硫胺時，發煙脂爲0 . 5〜3重 量份、維生素E爲〇 . 5〜3重量份者。又，發煙脂與維 生素E之摻合比一般由1〇〇:1〜1:1〇〇之重量比 、較佳者爲1 0 : 1〜1 : 1 0之重量比者、更佳者爲1 :3〜3 : 1之重量比。 經濟部智慧財產局員工消費合作社印製 本發明製劑中除上記成份之外，可摻合其他藥效成份 。做爲此藥效成份例者如：酪酸核黃素、核黃素、磷酸核 黃素鈉、腺嘌呤黃素二核苷酸等之維生素B 2類、尼克酸、 煙鹼酸、煙鹼酸醯胺等維生素B 3類、汎酸鈣、汎酸鈉、沉 酸醇、潘特生等維生素B 5類、鹽酸吡哆醇、磷酸吡哆醛等 維他命B 6類、醋酸羥鈷胺、鹽酸羥鈷胺、羥鈷胺、氰鈷胺 、甲鈷胺、銨胺醯胺等維生素B i 2類、葉酸、抗壞血酸、 抗壞血酸鈣、抗壞血酸鈉等維生素c類、生物素等維生素 Η類、醋酸松香油、棕櫚酸松香油、乙松香油、維生素A 油、肝油、強肝油等維生素A類、麥角骨化醇、膽骨化醇 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -6 - 1244921 A7 B7 ___ 五、發明説明（4 ) (請先閲讀背面之注意事項再填寫本頁) 、α骨化醇、骨化三醇、和杜仲骨化醇、二氫速巢醇等維 生素D類、維生素Κ 1、維生素Κ 2、等維生素κ類等脂 溶性維生素、鈣、鐵、磷、鎂、鉀、銅、碘、錳、硒、鋅 、鉻、鉬等礦物類、L 一丙胺酸、L 一天冬胺酸、L 一谷 胺酸、L 一羥基脯胺酸、L 一異白胺酸' L —白胺酸、L -苯基丙胺酸、L 一賴胺酸、L 一蛋胺酸、L 一蘇胺酸、 L 一色胺酸、L 一纈胺酸、L 一半胱胺酸、L 一胱胺酸、 L —氧化脯胺酸、L 一酪胺酸、L 一組胺酸、L 一脯胺酸 、L -絲胺酸、甘胺酸、L 一蘇胺酸、L 一精胺酸等胺基 酸類、牛黃、人蔘、薏仁、加工大蒜、鹿茸、淫羊草、茴 香、烏藥、延胡索、黃蓍、黃精、黃柏、黃連、海狗骨、 檟如樹、葛根、甘草、枸杞子、桂皮、吳茱萸、五味子、 經濟部智慧財產局員工消費合作社印製 .柴胡、山茱萸、山藥、地黃、芍藥、蛇麻子、熟地黃、縮 砂、紫五加、生薑、川芎、蒼求、大黃、大棗、澤瀉、知 母、釣藤、當歸、菟絲子、杜仲、肉緹蓉、麥門冬、反鼻 蛇、茯苓、牡丹皮、牡蠣、麻黃、巴西幌幌木、高良薑、 蜂王膠等生藥、生藥萃取物、漢方藥類、肌醇酸、乳淸酸 、葡糖醛酸內酯、葡糖醛酸醯胺、膠質白胺酸硫酸鈉、天 冬胺酸鉀、鎂等量混合物、r -谷維素、咖啡因、無水咖 啡因、氯化肉毒鹼、合成水滑石等例。此等藥效成份在不 損及本發明效果範圍內可添加1種或2種以上使用之。 本發明製劑係依常法，於適當口服製劑劑形中摻合雙 苯醯硫胺、發煙脂及維生素E後可調製之，做成錠劑、顆 粒劑、細粒劑、散劑、膠囊劑、軟膠囊劑、九劑、懸浮劑 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公董)一 ~ ~ 1244921 Α7 Β7 五、發明説明（5) (請先閱讀背面之注意事項再填寫本頁) 、乳劑、內服液劑、糖漿劑、乾糖漿劑等口服形態之固形 、半固形、及液狀形態之製劑使用之。另外，亦可做成微 膠囊、萘米膠囊、微球體、萘米球體等微小粒子後，再做 成前述之製劑者。 此等製劑之調製於必要時可添加安定（化）劑、界面 活性劑、可塑劑、潤滑化劑、潤滑劑、可溶（化）劑、還 原劑、緩衝劑、甜味劑、基劑、吸附劑、矯味劑、結合劑 、懸浮（化）劑、抗氧化劑、光滑化劑、塗層劑、劑皮、 潤濕劑、潤濕調整劑、塡充劑、消泡劑、淸涼化劑、著色 劑、著香劑、香料、糖衣劑、等張化劑、軟化劑、乳化劑 、粘稠劑、粘稠化劑、發泡劑、p Η調整劑、稀釋劑及賦 形劑、分散劑、崩散劑、崩散補助劑、崩散延長劑、芳香 劑、防濕劑、防腐劑、保存劑、溶解劑、溶解補助劑、溶 劑、流動化劑、防靜電劑、增量劑、保濕劑、附濕劑等製 劑添加物。 〔實施例〕 經濟部智慧財產局員工消費合作社印製 以下以實施例進行本發明更詳細說明，惟，本發明未 限定於此實施例者。 實施例 懸浮液劑之製造： 如表1所示處方，於精製水中分散，溶解雙苯醯硫胺 、發煙脂、及琥珀酸生育酚鈣，添加適當量之鹽酸後，調 本紙張尺度適用中國國家標準（CNS ) Α4規格（21〇χ297公釐） - 8- 12449211244921 A7 B7 V. Description of the invention (1) The present invention relates to an oral agent, and more specifically relates to an oral agent that improves the absorption of diphenylhydrazone and thiamine. (Please read the precautions on the back before filling out this page.) In the prior art, vitamins are based on sugars, lipids, and proteins as energy source components. Nowadays, classical vitamin deficiencies are not often seen, but when vitamins are insufficient, symptoms such as fatigue, burnout, and loss of appetite appear. Even smoking, stress will increase the consumption of vitamin C, drinking will increase the consumption of vitamin B i, resulting in deficiency of vitamin C, B i, latent vitamin deficiency or state-of-the-art vitamin deficiency are not non-existent today. Among the vitamins, water-soluble vitamins such as vitamin B i and vitamin C are excreted in the urine even if ingested in large amounts. Therefore, it is only necessary to ingest the necessary daily amount. However, it is not easy to take the necessary water-soluble vitamins at three meals a day. Therefore, supplements are often provided with vitamins that are insufficiently water-soluble. Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs. Generally, the absorption of water-soluble vitamins is better than that of fat-soluble vitamins. However, water-soluble vitamins also have many digestive tract absorption problems. For example, vitamin B i, one of the water-soluble vitamins, has limited absorption in the digestive tract, and is easily excreted outside the body. When thiaminase-producing bacteria are released in the intestine, those with vitamin B 1 deficiency are known. Therefore, in order to improve vitamin B: deficiency, to improve the absorption of thiamine hydrochloride in the digestive tract, and to discuss the increase of fat-soluble derivatives of vitamin B1, those who are easily absorbable derivatives should be synthesized. Thiamine, phenothiamine, ethoxycarbonylthiamine, secoximine, dithiothiamine, diphenylthiothiamine, bisisothiamine, etc. are used to achieve higher blood concentrations. However, for this benzene-4-this paper size is applicable to the Chinese National Standard (CNS) A4 specification (210X 297 mm) 1244921 A7 B7 V. Description of the invention (2) In thiamine, it is added by adding excipients, etc. It is known that the poor absorption properties of the product are expected to provide a method for optimizing absorption from the digestive tract. (Please read the precautions on the back before filling out this page.) Therefore, the subject of the present invention is to provide a vitamin B 1 containing formulation with better absorption. In view of this situation, the present inventors conducted a precise discussion on the absorption of various digestive tracts of vitamin B: and unexpectedly found that when diphenylhydrazine is blended with fuming fat and vitamin E, diphenyl can be quickly absorbed from the digestive tract. The absorption of thiamine and the increase in the amount of thiamine in the blood plasma further complete the present invention. That is, it is a feature of the present invention to provide an oral agent blended with diphenylsulfanamine, fuming fat and vitamin E. [Forms of Implementation of the Invention] The diphenylhydrazone used in the oral preparation of the present invention (hereinafter referred to as "the preparation of the present invention") is a chemical name: N'-Ι ^ ΐΜοΙ ^ Ι ^ -Ι ^ -ί ^ βηζογΙοχ ^- θΐΙιγΙ]-l-methyl-2, l-ethenediyl]] bis [N-[(4_amino-2-methyl-5-pyrimidinyl) methyl] formamide], molecular formula: Printed by the Consumers ’Cooperative of Intellectual Property Bureau, Ministry of Economic Affairs, C 3 8 Η 4 2 N 8 0 6 S 2, molecular weight: 70.7 09 3 of thiamine derivatives, 114 mg of bisphenazine thiamine equivalent to 1,000 mg of thiamine hydrochloride compounds. In addition, the fuming lipid (chemical name: 2-1 ^ \ 71- (2-hydroxymethyl) -1,3-propandiol trinicotinate) used in the preparation of the present invention has the effect of improving blood flow, inhibiting platelet aggregation, and cellulose Peripheral vasodilators with pharmacological effects such as dissolution, as peripheral circulation disorders, frostbite, and frostbite such as Raynaud's disease, idiopathic idiopathic disease, and obstructive arteriosclerosis. This paper applies Chinese national standards (CNS) A4 Specifications (210X297 mm) -5- 1244921 A7 _ B7 V. Description of the invention (3) Those who are used. (Please read the notes on the back before filling this page.) Moreover, the vitamin E used in the preparation of the present invention refers to all vitamins in general, ideal specific examples such as: succinic acid d-alpha-tocopherol, succinic acid d 1 -α-tocopherol, succinic acid d 1-α-tocopherol calcium, d-α-tocopheryl acetate, d 1-α-tocopheryl acetate, d-α-tocopherol, dl-α-tocopherol, etc. example. In the preparation of the present invention, when the blending amount of bisphenazine, fuming fat, and vitamin E is 1 part by weight of bisphenazine, the fuming fat is 0.3 to 300 parts by weight, vitamin E. 0.3 to 300 parts by weight, preferably when 1 part by weight of bisphenazine, fuming fat is 0.5 to 3 parts by weight, and vitamin E is 0.5 to 3 parts by weight. In addition, the blending ratio of fuming fat and vitamin E is generally from a weight ratio of 100: 1 to 1: 100, preferably a weight ratio of 10: 1 to 1:10, and more preferably It is a weight ratio of 1: 3 to 3: 1. Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs. In addition to the above-mentioned ingredients in the preparation of the present invention, other medicinal ingredients may be blended. Examples of such medicinal ingredients are: vitamin B 2 such as riboflavin caseinate, riboflavin, sodium riboflavin phosphate, adenine flavin dinucleotide, nicotinic acid, nicotinic acid, and nicotinic acid. Vitamin B 3 such as scopolamine, vitamin B 5 such as calcium pantothenate, sodium pantothenate, precipitating alcohol, Pantex, vitamin B 6 such as pyridoxine hydrochloride, pyridoxal phosphate, hydroxycobalamin acetate, hydroxycobalt hydrochloride Vitamins B 2 such as amines, hydroxycobalamin, cyanocobalamin, mecobalamin, ammonium amines, folic acid, ascorbic acid, vitamin c such as calcium ascorbate, sodium ascorbate, vitamins such as biotin, rosin acetate, Palmitic rosin oil, rosin oil, vitamin A oil, liver oil, strong liver oil and other vitamins A, ergocalciferol, and cholecalciferol. This paper applies Chinese national standard (CNS) A4 specifications (210X297 mm) -6 -1244921 A7 B7 ___ V. Description of the invention (4) (Please read the precautions on the back before filling out this page), α-calciferol, calcitriol, eucommitol, dihydrotasitol, and other vitamin D Vitamin K1, Vitamin K2, etc. Biotin, calcium, iron, phosphorus, magnesium, potassium, copper, iodine, manganese, selenium, zinc, chromium, molybdenum and other minerals, L-alanine, L-aspartic acid, L-glutamine, L-hydroxyl Proline, L-isoleucine 'L-leucine, L-phenylalanine, L-lysine, L-methionine, L-threonine, L-tryptophan, L-valerate L-amino acid, L-cysteine, L-cysteine, L-oxyproline, L-tyrosine, L-group of amines, L-proline, L-serine, glycine, Amino acids such as L-threonine, L-arginine, bezoar, human coriander, coix seed, processed garlic, velvet antler, yarrow, fennel, black yam, fragrans, scutellaria baicalensis, huangjing, cork, pupae, fur seal Bone, sassafras tree, pueraria root, licorice, wolfberry, cinnamon, dogwood, Schisandra chinensis, printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs. , Ziwujia, Ginger, Chuanxiong, Cangqiu, Rhubarb, Jujube, Alisma, Zhimu, Rattan, Angelica, Cuscuta, Eucommia, Cistanche, Ome, Snake, Poria, Peony Skin, Oyster, Ephedra, Brazilian Horde, Galangal, Royal Jelly and other crude drugs, crude drug extracts, Chinese herbal medicines, inositol, lactate, glucuronide, glucose Examples of ammonium uronic acid, colloidal sodium glutamate, potassium aspartate, magnesium equivalents, r-oryzanol, caffeine, anhydrous caffeine, carnitine chloride, and synthetic hydrotalcite. These medicinal ingredients may be used by adding one or more kinds within the range that does not impair the effect of the present invention. The preparation of the present invention is prepared by mixing diphenylsulfanil, fuming fat and vitamin E in appropriate oral preparations, and can be prepared into lozenges, granules, fine granules, powders, capsules. , Soft capsules, nine agents, suspending agents This paper is applicable to Chinese National Standards (CNS) A4 specifications (210X297 public directors) I ~ ~ 1244921 Α7 Β7 V. Description of the invention (5) (Please read the notes on the back before filling This page), emulsion, oral solution, syrup, dry syrup and other oral forms of solid, semi-solid, and liquid form preparations are used. In addition, microparticles such as microcapsules, naphthalene capsules, microspheres, and naphthalene spheres can be made into the aforementioned preparations. The preparation of these preparations can add stabilizers, surfactants, plasticizers, lubricating agents, lubricants, soluble agents, reducing agents, buffering agents, sweeteners, bases, Adsorbents, flavoring agents, binding agents, suspension (chemical) agents, antioxidants, smoothing agents, coating agents, coatings, wetting agents, wetting regulators, fillers, defoamers, depressants , Coloring agent, flavoring agent, flavor, sugar coating agent, isotonicity agent, softener, emulsifier, thickener, thickener, foaming agent, p Η modifier, diluent and excipient, dispersion Agents, disintegrating agents, disintegrating aids, disintegrating extenders, fragrances, moisture-proofing agents, preservatives, preservatives, dissolving agents, dissolving aids, solvents, fluidizing agents, antistatic agents, extenders, moisturizers Additives such as agents, hygroscopic agents. [Embodiment] Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs The present invention will be described in more detail in the following embodiment, but the invention is not limited to this embodiment. Example suspension preparation: Disperse in purified water as shown in Table 1, dissolve diphenylhydrazine, fuming fat, and calcium tocopherol succinate, add the appropriate amount of hydrochloric acid, and adjust the paper size. China National Standard (CNS) Α4 Specification (21 × 297 mm)-8- 1244921
7 7 A B 五、發明説明（6) 整p Η後，以精製水做成全量1 〇 〇 m L，製造懸浮液劑 (本發明品1 )。又，做爲比較品者以使用未摻合琥珀酸 生育酚鈣者（比較品1 )，未摻合發煙脂者（比較品2 ) ，及兩者均未摻合者（比較品3 )。 〔表1〕 本發明品1 比較品1 比較品2 比較品3 雙苯醯硫胺 1 1 1 1 發煙脂* 1 1 — — 琥珀酸生育酚鈣* * 1 — 1 — 表中値之單位均爲克。 * :同仁醫藥化工（股份）製 * * :日淸製粉（股份）製 (請先閲讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 試驗例 吸收性試驗： C 1 )試驗方法 吸收性試驗中由試驗實施前一天開始絕食之9週齡雄 S D系實驗鼠做成1群5隻使用之。試驗藥劑使用本發明 品1、比較品1〜3。使各藥劑於各群實驗鼠中強制投服 2 0 m g / k g之雙苯醯硫胺。使血漿中硫胺濃度於各藥 劑投用前、投用後〇 . 5、 1、2、3、4、8、 1 2及 2 4小時後，採取1 J血液進行離心分離後，取得之血漿 做爲試料，藉由Η P L C進行測定之。 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐） -9- 1244921 A7 B7 五、發明説明（7 ) (2 )結果 減去投服如之血發中硫妝濃度之各採血時硫胺濃度如 第1圖所示，A U C ◦ —如表2所示。本發明品1顯示比 比較品1、2、3投服後血漿中呈現較高硫胺濃度者， A U C値亦較高者。 〔表2〕 試驗藥劑 A U C 〇 - - (ng · hr · mL'1) 本發明品1 3461± 652 比較品1 2610± 359 比較品2 2421± 324 比較品3 2503± 561 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 〔發明效果〕 本發明口服藥劑係於雙苯醯硫胺中摻合發煙脂及維生 素E後，提昇雙苯醯硫胺之消化管的吸收性者，可提高生 體可利用率者。 因此，投用於維生素B i缺乏者之外，潛在性維生素 B i缺乏者或境界型維生素B i缺乏者後，可充份取得所攝 取雙苯醯硫胺之效果。 〔圖面之簡單說明〕 〔圖1〕圖1係代表血漿中硫胺濃度與時間相互關係 之圖面者。 本紙張尺度適用中國國家標準（CNS ) A4規格（210X 297公釐） -10-7 7 A B V. Description of the invention (6) After adjusting p 整, make a total amount of 1000 ml with purified water to produce a suspension agent (product 1 of the present invention). In addition, as a comparative product, those who did not incorporate calcium tocopherol succinate (Comparative Product 1), those who did not incorporate fuming fat (Comparative Product 2), and those who did not incorporate both (Comparative Product 3) . [Table 1] Inventive product 1 Comparative product 1 Comparative product 2 Comparative product 3 Diphenylhydrazine 1 1 1 1 Smoking fat * 1 1 — —Tocopherol succinate * * 1 — 1 — Unit of 値 in the table Both are grams. *: Tongren Pharmaceutical Chemical (shareholding) system * *: Nissin flour milling (shareholding) system (please read the precautions on the back before filling out this page) The test case printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs Absorption test: C 1 ) Test method In the absorptivity test, a group of 5 male SD rats of 9 weeks of age who had been on a hunger strike the day before the test was started and used. As the test agent, the product of the present invention 1 and the comparative products 1 to 3 were used. Each agent was forcibly dosed with 20 mg / k g of diphenylhydrazone in each group of experimental rats. The concentration of thiamine in the plasma was 0.5, 1, 2, 3, 4, 8, 12, and 24 hours after the administration of each drug, and 1 J of blood was taken for centrifugation to obtain plasma. As a sample, it was measured by Η PLC. This paper size applies the Chinese National Standard (CNS) A4 (210X297 mm) -9-1244921 A7 B7 V. Description of the invention (7) (2) Results minus the sulfur concentration in the hair when taken The thiamine concentration is shown in Figure 1, and AUC ◦ is shown in Table 2. The product 1 of the present invention showed a higher thiamine concentration in the plasma after administration than the comparative products 1, 2, and 3, and the A U C 値 was also higher. [Table 2] Test agent AUC 〇--(ng · hr · mL'1) Inventive product 1 3461 ± 652 Comparative product 1 2610 ± 359 Comparative product 2 2421 ± 324 Comparative product 3 2503 ± 561 (Please read the first Note: Please fill in this page again.) Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs. [Inventive effect] The oral medicament of the present invention is blended with fuming fat and vitamin E in diphenylhydrazine to increase the Absorptive gastrointestinal can improve the availability of the body. Therefore, after being administered to people with a deficiency of vitamin B i, those with a potential deficiency of vitamin B i or those with a state-level vitamin B i deficiency can fully obtain the effect of the taken bisphenylhydramine. [Simplified description of the drawing] [Fig. 1] Fig. 1 is a drawing representing the relationship between the concentration of thiamine in plasma and time. This paper size applies to Chinese National Standard (CNS) A4 (210X 297 mm) -10-